Table 1. Baseline Patient and Tumor Characteristicsa.
| Characteristic | Study group | |
|---|---|---|
| EP (n = 407) | EC-P (n = 406) | |
| Age, y | ||
| Median (IQR) [range] | 49 (42-56) [23-70] | 48 (41-56) [24-77] |
| <55 | 287 (70.5) | 294 (72.4) |
| ≥55 | 120 (29.5) | 112 (27.6) |
| Height, median (IQR) [range], cm | 160 (156-164) [145-173] | 160 (156-164) [141-176] |
| Weight, median (IQR) [range], kg | 63 (57-70) [40-89] | 63 (58-70) [40-105] |
| Tumor size, cm | ||
| <2 | 210 (51.6) | 212 (52.2) |
| 2-5 | 175 (43.0) | 178 (43.8) |
| >5 | 22 (5.4) | 16 (3.9) |
| No. of nodes involved | ||
| 1-3 | 229 (56.3) | 208 (51.2) |
| 4-9 | 111 (27.3) | 120 (29.6) |
| ≥10 | 67 (16.5) | 78 (19.2) |
| Histological grade | ||
| 1 | 26 (6.4) | 13 (3.2) |
| 2 | 277 (68.1) | 276 (68.0) |
| 3 | 104 (25.6) | 117 (28.8) |
| TNM stage | ||
| II | 217 (53.3) | 213 (52.5) |
| III | 190 (46.7) | 193 (47.5) |
| Lymphovascular invasion | ||
| Yes | 117 (28.7) | 126 (31.0) |
| No | 290 (71.3) | 280 (69.0) |
| Luminal subtype | ||
| A | 143 (35.1) | 124 (30.5) |
| B | 264 (64.9) | 282 (69.5) |
| Menopausal status (at diagnosis) | ||
| Premenopausal | 243 (59.7) | 241 (59.4) |
| Postmenopausal | 164 (40.3) | 165 (40.6) |
| Ki67 level | ||
| ≤30% | 303 (74.4) | 284 (70.0) |
| >30% | 65 (16.0) | 77 (19.0) |
| Unknown | 39 (9.6) | 45 (11.1) |
| Type of surgery | ||
| Modified radical mastectomy | 341 (83.8) | 347 (85.5) |
| Breast-conserving surgery | 66 (16.2) | 55 (13.5) |
| Endocrine therapy | 394 (96.8) | 393 (96.8) |
| Types of endocrine therapy | ||
| Tamoxifen | 153 (38.8) | 147 (37.4) |
| Tamoxifen plus OFS | 6 (1.5) | 8 (2.0) |
| AI | 130 (33.0) | 122 (31.0) |
| AI plus OFS | 94 (23.9) | 106 (27.0) |
| Otherb | 11 (2.8) | 10 (2.5) |
| Duration of endocrine therapy, y | ||
| <2 | 20 (5.1) | 24 (6.1) |
| 2-5 | 88 (22.3) | 115 (29.3) |
| >5 | 246 (62.4) | 217 (55.2) |
| Unknown | 40 (10.2) | 37 (9.4) |
| Radiotherapy | 257 (63.1) | 258 (63.5) |
Abbreviations: AI, aromatase inhibitor; EC-P, epirubicin and cyclophosphamide followed by paclitaxel; EP, epirubicin plus paclitaxel; OFS, ovarian function suppressor.
a
Unless otherwise indicated, data are presented as No. (%) of patients. Percentages have been rounded and may not total 100.
b
The regimens were changed during the endocrine therapy.